Journal Club
1. Spectrum Of Pulmonary Fungal Pathogens And Antifungal Drug Susceptibility Among TB Relapse And Retreatment Samples At Selected Health Facilities In Kenya - PhD Research Update
0
IAVI-W001 Study Launched at the KAVI-Institute of Clinical Research
On 24th September 2019, the first volunteer was enrolled in the IAVI-W001 study at the KAVI-Institute of Clinical Research (KAVI-ICR) of the University of Nairobi. The occasion marks the beginning of the 12th HIV vaccine clinical trial to be conducted at KAVI-ICR since 2001. This is a first-in-human study that uses a Native-trimer HIV envelope design that will hopefully stimulate broadly neutralizing antibodies against HIV.
0
KAVI-ICR Advances HIV Vaccine Research and Global Partnerships at AIDS 2026
Rio de Janeiro, Brazil — KAVI–Institute of Clinical Research (KAVI-ICR), University of Nairobi, strengthened its global engagement in HIV vaccine research through active participation at AIDS 2026, the 26th International AIDS Conference, held in Rio de Janeiro, Brazil, from 26 to 31 July 2026 under the theme “Rethink. Rebuild. Rise.”